About

Science

Pipeline

Investor Information

Contact Us

Investor Information

Investor Information

Press Releases

Jun 1, 2020 7:00 AM EDT Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update
May 28, 2020 7:00 AM EDT Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020
May 21, 2020 7:00 AM EDT Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office
May 18, 2020 7:00 AM EDT Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liver Fat and Fibrosis
May 15, 2020 7:00 AM EDT Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
Apr 14, 2020 7:00 AM EDT Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET
Apr 13, 2020 6:30 AM EDT Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
Apr 7, 2020 9:00 AM EDT Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson
Mar 30, 2020 7:00 AM EDT Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
Mar 27, 2020 7:00 AM EDT Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update

<< Previous
1
2
3
4
5
6
7
8
9
10
...29
Next >>

Show All